Valuation: Outlook Therapeutics, Inc.

Market Cap 145M 129M 120M 110M 206M 13.96B 208M 1.46B 566M 7.13B 544M 532M 22.91B P/E 2026 *
-1.03x
P/E 2027 * -2.75x
Enterprise Value 145M 129M 120M 110M 206M 13.96B 208M 1.46B 566M 7.13B 544M 532M 22.91B EV / Sales 2026 *
212x
EV / Sales 2027 * 3.29x
Free-Float
86.07%
Yield 2026 *
-
Yield 2027 * -
1 day+0.42%
1 week-4.12%
Current month+3.84%
1 month-10.65%
3 months-58.93%
6 months+171.92%
Current year-62.31%
1 week 0.53
Extreme 0.5314
0.63
1 month 0.53
Extreme 0.5314
0.74
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
2.54
3 years 0.16
Extreme 0.1611
18
5 years 0.16
Extreme 0.1611
46.2
10 years 0.16
Extreme 0.1611
704
Manager TitleAgeSince
Chief Executive Officer 54 30/06/2025
Director of Finance/CFO 59 31/08/2026
Chief Tech/Sci/R&D Officer - 18/01/2023
Director TitleAgeSince
Director/Board Member 65 10/12/2015
Chairman 41 30/01/2025
Director/Board Member 50 30/10/2017
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Free

Chief Financial Officer

500,000 0.3122%
14/08/26 Buy

Chief Executive Officer

202,020 0.0832%
14/08/26 Buy

Chief Executive Officer

303,030 0.1249%
Change 5-day change 1-year change 3-year change Capi.($)
+0.42%-4.12%-43.82%-86.96% 144M
+4.16%+3.42%+49.37%+94.17% 74.16B
-0.37%-3.81%+19.75%+78.12% 57.39B
+1.63%-1.61%+3.83%+36.89% 47.64B
+0.50%+2.94%+344.62%+722.17% 44.29B
+3.05%-1.80%+28.78%+34.51% 42.5B
+1.00%-1.46%+5.17%+111.90% 40.71B
-0.54%+2.41%+9.31%+58.85% 30.97B
+4.42%+7.94%+37.50%+32.15% 28.53B
+0.76%-1.45%-7.44%-11.12% 24.34B
Average +1.48%-0.54%+44.71%+107.07% 39.07B
Weighted average by Cap. +1.74%-0.41%+58.47%+137.43%

Financials

2026 *2027 *
Net sales 683K 609K 567K 516K 972K 65.75M 980K 6.86M 2.67M 33.56M 2.56M 2.51M 108M 44.07M 39.32M 36.63M 33.33M 62.77M 4.24B 63.24M 443M 172M 2.17B 165M 162M 6.96B
Net income -65.1M -58.08M -54.11M -49.24M -92.73M -6.27B -93.41M -654M -254M -3.2B -244M -239M -10.29B -44.43M -39.64M -36.93M -33.61M -63.29M -4.28B -63.76M -446M -174M -2.18B -167M -163M -7.02B
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
05/10/26 US$0.5955 +0.42% 4,673,102
02/10/26 US$0.5930 +3.13% 5,619,583
01/10/26 US$0.5750 +0.26% 7,068,830
30/09/26 US$0.5735 -8.34% 9,011,677
29/09/26 US$0.6257 +0.74% 4,583,135
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.5955USD
Average target price
5.025USD
Spread / Average Target
+743.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock